61 /100
HIGH RISK
Score updated Jul 14, 2026

IRD — Opus Genetics, Inc. Dilution Risk Tracker

Track IRD dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track IRD — Get alerts when the score changes →

As of July 14, 2026, Opus Genetics, Inc. (IRD) has a DilutionWatch DilutionScore of 61/100, rated HIGH dilution risk. Opus Genetics, Inc. has a market capitalization of $354.88M, 81.40M shares outstanding, 79 institutional holders tracked. Key dilution vectors include shelf registration capacity of $25.00M, approximately 23 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
25
📊 Float Risk
45
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

Watch
Minor dilution signals detected
16%
💰 Capital Raise 20%
• Active shelf registration ($25M, 7% of market cap)
🔄 Reverse Split 15%
• 52-week low $0.90 has breached $1
📉 Score Deterioration 10%
• Score in HIGH risk zone (61/100)
🔔 Track IRD — Get forecast alerts →

💹 Market Data

Market Cap$354.88M
Shares Outstanding81.40M
Float34.48M
Cash$59.96M
Debt$1.20M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 87.4% shares (2026Q1 vs prior)
79 institutional holders · 52.36M shares
#1 Caligan Partners LP 6.08M shares
#2 ADAGE CAPITAL PARTNERS GP, L.L.C. 6.03M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 4.90M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest8.23M
Days to Cover5.2
% of Float23.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2025
xbrl XBRL WARRANT Dec 31, 2025
8-K 8K EVENT Apr 07, 2026
4 INSIDER TRANSACTION Mar 18, 2026
4 INSIDER TRANSACTION Mar 18, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for IRD Shareholders

Opus Genetics, Inc. (IRD) has a DilutionScore of 61/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

The most significant dilution vector for IRD is its shelf registration capacity of $25.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely.

DilutionWatch tracks over 25 SEC filing types for IRD in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for IRD alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding Shelf Registrations →
Track IRD Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking IRD — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for IRD
📊 IRD FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 IRD Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.